|
1
|
Lee J, Kim WS, Park YH, Park SH, Park KW,
Kang JH, Lee SS, Lee SI, Lee SH, Kim K, et al: Nasal-type NK/T cell
lymphoma: Clinical features and treatment outcome. Br J Cancer.
92:1226–1230. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tse E and Kwong YL: The diagnosis and
management of NK/T-cell lymphomas. J Hematol Oncol. 10:852017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tse E and Kwong YL: How I treat NK/T-cell
lymphomas. Blood. 121:4997–5005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Makita S and Tobinai K: Clinical features
and current optimal management of natural killer/T-cell lymphoma.
Hematol Oncol Clin North Am. 31:239–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iqbal J, Kucuk C, Deleeuw RJ, Srivastava
G, Tam W, Geng H, Klinkebiel D, Christman JK, Patel K, Cao K, et
al: Genomic analyses reveal global functional alterations that
promote tumor growth and novel tumor suppressor genes in natural
killer-cell malignancies. Leukemia. 23:1139–1151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karube K, Nakagawa M, Tsuzuki S, Takeuchi
I, Honma K, Nakashima Y, Shimizu N, Ko YH, Morishima Y, Ohshima K,
et al: Identification of FOXO3 and PRDM1 as tumor-suppressor gene
candidates in NK-cell neoplasms by genomic and functional analyses.
Blood. 118:3195–3204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Küçük C, Iqbal J, Hu X, Gaulard P, De
Leval L, Srivastava G, Au WY, McKeithan TW and Chan WC: PRDM1 is a
tumor suppressor gene in natural killer cell malignancies. Proc
Natl Acad Sci USA. 108:20119–20124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Y, de Leval L and Gaulard P:
Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract
Res Clin Haematol. 26:57–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang L, Nong L, Zhang S, Zhao J, Ti H,
Dong Y, Zhang B and Li T: The downregulation of PRDM1/Blimp-1 is
associated with aberrant expression of miR-223 in extranodal
NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res. 33:72014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang L, Zhang Z, Wang Y, Nong L, Zheng Y,
Qu L, Zhang B and Li T: The genetic deletion of 6q21 and PRDM1 and
clinical implications in extranodal NK/T cell lymphoma, nasal type.
Biomed Res Int. 2015:4354232015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Z, Liang L, Li D, Nong L, Liu J, Qu
L, Zheng Y, Zhang B and Li T: Hypermethylation of PRDM1/Blimp-1
promoter in extranodal NK/T-cell lymphoma, nasal type: An evidence
of predominant role in its downregulation. Hematol Oncol.
35:645–654. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee S, Park HY, Kang SY, Kim SJ, Hwang J,
Lee S, Kwak SH, Park KS, Yoo HY, Kim WS, et al: Genetic alterations
of JAK/STAT cascade and histone modification in extranodal
NK/T-cell lymphoma nasal type. Oncotarget. 6:17764–17776.
2015.PubMed/NCBI
|
|
13
|
Ng SB, Selvarajan V, Huang G, Zhou J,
Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, et al:
Activated oncogenic pathways and therapeutic targets in extranodal
nasal-type NK/T cell lymphoma revealed by gene expression
profiling. J Pathol. 223:496–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Shen Y, Wang S, Shen Q and Zhou X:
The role of STAT3 in leading the crosstalk between human cancers
and the immune system. Cancer Lett. 415:117–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen YW, Guo T, Shen L, Wong KY, Tao Q,
Choi WW, Au-Yeung RK, Chan YP, Wong ML, Tang JC, et al:
Receptor-type tyrosine-protein phosphatase κ directly targets STAT3
activation for tumor suppression in nasal NK/T-cell lymphoma.
Blood. 125:1589–1600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coppo P, Gouilleux-Gruart V, Huang Y,
Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues
P, Gaulard P, et al: STAT3 transcription factor is constitutively
activated and is oncogenic in nasal-type NK/T-cell lymphoma.
Leukemia. 23:1667–1678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Küçük C, Jiang B, Hu X, Zhang W, Chan JK,
Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al: Activating
mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK
cells. Nat Commun. 6:60252015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cazzola M: Introduction to a review
series: The 2016 revision of the WHO classification of tumors of
hematopoietic and lymphoid tissues. Blood. 127:2361–2364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robertson MJ, Cochran KJ, Cameron C, Le
JM, Tantravahi R and Ritz J: Characterization of a cell line, NKL,
derived from an aggressive human natural killer cell leukemia. Exp
Hematol. 24:406–415. 1996.PubMed/NCBI
|
|
20
|
Gong JH, Maki G and Klingemann HG:
Characterization of a human cell line (NK-92) with phenotypical and
functional characteristics of activated natural killer cells.
Leukemia. 8:652–658. 1994.PubMed/NCBI
|
|
21
|
Yodoi J, Teshigawara K, Nikaido T, Fukui
K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, et al:
TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL 2
receptor on a natural killer-like cell line (YT cells). J Immunol.
134:1623–1630. 1985.PubMed/NCBI
|
|
22
|
Garcia JF, Roncador G, Garcia JF, Sánz AI,
Maestre L, Lucas E, Montes-Moreno S, Fernandez Victoria R,
Martinez-Torrecuadrara JL, Marafioti T, et al: PRDM1/BLIMP-1
expression in multiple B and T-cell lymphoma. Haematologica.
91:467–474. 2006.PubMed/NCBI
|
|
23
|
Nie K, Gomez M, Landgraf P, Garcia JF, Liu
Y, Tan LH, Chadburn A, Tuschl T, Knowles DM and Tam W:
MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in
Hodgkin/Reed-Sternberg cells: A potential pathogenetic lesion in
Hodgkin lymphomas. Am J Pathol. 173:242–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nie K, Zhang T, Allawi H, Gomez M, Liu Y,
Chadburn A, Wang YL, Knowles DM and Tam W: Epigenetic
down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in
diffuse large B cell lymphomas: A potential role of the microRNA
let-7. Am J Pathol. 177:1470–1479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan J, Zhang F and Niu R: Multiple
regulation pathways and pivotal biological functions of STAT3 in
cancer. Sci Rep. 5:176632015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu ZL, Song YQ, Shi YF and Zhu J: High
nuclear expression of STAT3 is associated with unfavorable
prognosis in diffuse large B-cell lymphoma. J Hematol Oncol.
4:312014.
|
|
27
|
Khanna P, Chua PJ, Bay BH and Baeg GH: The
JAK/STAT signaling cascade in gastric carcinoma (Review). Int J
Oncol. 47:1617–1626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bouchekioua A, Scourzic L, de Wever O,
Zhang Y, Cervera P, Aline-Fardin A, Mercher T, Gaulard P, Nyga R,
Jeziorowska D, et al: JAK3 deregulation by activating mutations
confers invasive growth advantage in extranodal nasal-type natural
killer cell lymphoma. Leukemia. 28:338–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nairismägi M, Gerritsen ME, Li ZM, Wijaya
GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, et al:
Oncogenic activation of JAK3-STAT signaling confers clinical
sensitivity to PRN371, a novel selective and potent JAK3 inhibitor,
in natural killer/T-cell lymphoma. Leukemia. 32:1147–1156. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ,
Ahn YO, Keam B, Park HH, Kim DW, Kim CW and Heo DS: Novel
JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal
type. Am J Pathol. 187:980–986. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L,
Tao Y and Cao Y: Epstein-Barr virus encoded LMP1 regulates cyclin
D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp
Clin Cancer Res. 32:902013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dobashi A, Tsuyama N, Asaka R, Togashi Y,
Ueda K, Sakata S, Baba S, Sakamoto K, Hatake K and Takeuchi K:
Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal
type. Genes Chromosomes Cancer. 55:460–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY,
Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, et al: Exome sequencing
identifies somatic mutations of DDX3X in natural killer/T-cell
lymphoma. Nat Genet. 47:1061–1066. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koo GC, Tan SY, Tang T, Poon SL, Allen GE,
Tan L, Chong SC, Ong WS, Tay K, Tao M, et al: Janus kinase
3-activating mutations identified in natural killer/T-cell
lymphoma. Cancer Discov. 2:591–597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kimura H, Karube K, Ito Y, Hirano K,
Suzuki M, Iwata S and Seto M: Rare occurrence of JAK3 mutations in
natural killer cell neoplasms in Japan. Leuk Lymphoma. 55:962–963.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ryu JG, Lee J, Kim EK, Seo HB, Park JS,
Lee SY, Moon YM, Yoo SH, Park YW, Park SH, et al: Treatment of
IL-21R-Fc control autoimmune arthritis via suppression of STAT3
signal pathway mediated regulation of the Th17/Treg balance and
plasma B cells. Immunol Lett. 163:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Barnes NA, Stephenson S, Cocco M, Tooze RM
and Doody GM: BLIMP-1 and STAT3 counterregulate microRNA-21 during
plasma cell differentiation. J Immunol. 189:253–260. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heidelberger S, Zinzalla G, Antonow D,
Essex S, Basu BP, Palmer J, Husby J, Jackson PJ, Rahman KM,
Wilderspin AF, et al: Investigation of the protein alkylation sites
of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg
Med Chem Lett. 23:4719–4722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Quintás-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and
resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Banerjee S, Biehl A, Gadina M, Hasni S and
Schwartz DM: JAK-STAT signaling as a target for inflammatory and
autoimmune diseases: Current and future prospects. Drugs.
77:521–546. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ando S, Kawada JI, Watanabe T, Suzuki M,
Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, et al:
Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth
in Epstein-Barr virus-associated T and natural killer cell lymphoma
cells. Oncotarget. 7:76793–76805. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vainchenker W, Leroy E, Gilles L, Marty C,
Plo I and Constantinescu SN: JAK inhibitors for the treatment of
myeloproliferative neoplasms and other disorders. F1000Res.
7:822018. View Article : Google Scholar : PubMed/NCBI
|
